Instrument Inactif

Communiqués Intercept Pharmaceuticals, Inc.

Actions

ICPT

US45845P1084

Recherche biotechnologique et médicale

Communiqués

09/09/24	Intercept Pharmaceuticals, Inc. - Findings from COBALT Trial, Including External Control Arm, Published in The American Journal of Gastroenterology	AQ
09/05/24	Intercept Announces New PBC Data Analyses to be Presented at Digestive Disease Week® 2024 Conference	AQ
29/02/24	Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC	AQ
13/11/23	Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting® 2023	AQ
10/11/23	Intercept Announces New Findings from Long-term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD The Liver Meeting® 2023	AQ
09/11/23	Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.	AQ
08/11/23	Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.	AQ
07/11/23	Intercept: Q3 Earnings Snapshot	AQ
16/10/23	INTERCEPT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intercept Pharmaceuticals, Inc. - ICPT	BU
28/09/23	INTERCEPT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intercept Pharmaceuticals, Inc. - ICPT	BU
26/09/23	ICPT Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Intercept Pharmaceuticals to Alfasigma	AQ
26/09/23	Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases	AQ
08/09/23	Intercept Pharmaceuticals : Corporate Presentation – September 2023	PU
05/09/23	Intercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences	AQ
02/08/23	Intercept Pharmaceuticals : Corporate Presentation – August 2023	PU
02/08/23	Intercept: Q2 Earnings Snapshot	AQ
02/08/23	Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updates	AQ
26/07/23	Intercept to Announce Second Quarter 2023 Financial Results on August 2, 2023	AQ
26/06/23	Intercept Pharmaceuticals : Corporate Presentation – June 2023	PU
25/06/23	Intercept Pharmaceutical : Intercept Pharmaceuticals	PU
23/06/23	Intercept Announces Restructuring to Strengthen Focus on Rare and Serious Liver Diseases and Significantly Reduce Operating Expenses	AQ
23/06/23	INTERCEPT PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
23/06/23	Intercept Pharmaceuticals : EASL 2023 Podium Presentation of OCA-bezafibrate Combination Planned Interim Analysis	PU
23/06/23	Intercept Presents New Data Showing Significant Impact of OCA-bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage	AQ
22/06/23	Intercept Receives Complete Response Letter from FDA for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH	AQ